Kedrion to Market RYPLAZIM to Treat Rare Disease
RYPLAZIM treats plasminogen deficiency type 1, also known as C-PLGD, an ultra-rare condition affecting less than 2,000 people in the U.S.
- By BSTQ Staff
Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, is now marketing and distributing RYPLAZIM (plasminogen human-tvmh) in the United States to treat plasminogen deficiency type 1, also known as C-PLGD, an ultra-rare condition affecting less than 2,000 people in the U.S. A lifelong disease, the most severe symptoms of C-PLGD are observed in infants and children. And, given its rarity, the condition is probably underdiagnosed in the U.S.
“The most important mission at Kedrion Biopharma is to improve the lives of people with rare and serious diseases,” said Val Romberg, CEO. “As the newest addition to our growing portfolio of products, RYPLAZIM is an excellent example of that dedication. RYPLAZIM meets an urgent unmet medical need for people who face plasminogen deficiency type 1, a potentially devastating, but treatable, medical condition. We are pleased and gratified to be in a position now to help these patients.”
References
Kedrion Biopharma to Commercialize RYPLAZIM® (plasminogen, human-tvmh) in U.S. to Address Unmet Need in Patients with Ultra-Rare Condition: Plasminogen Deficiency Type 1. Kedrion Biopharma press release, Oct. 20, 2021. Accessed at www.biospace.com/article/ releases/kedrion-biopharma-to-commercialize-ryplazim-plasminogen-human-tvmh-in-u-s-to-address-unmet-need-in-patients-with-ultra-rare-condition-plasminogen-deficiency-type-1.
